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Lithium has long been used as a mood stabilizer in the treatment of manic-depressive (bipolar) 
disorder. Recent studies suggest that lithium has neuroprotective properties and may be useful 
in the treatment of acute brain injuries such as ischemia and chronic neurodegenerative diseases 
such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral 
sclerosis. One of the most important neuroprotective properties of lithium is its anti-apoptotic 
action. Ethanol is a neuroteratogen and fetal alcohol spectrum disorders (FASD) are caused by 
maternal ethanol exposure during pregnancy. FASD is the leading cause of mental retardation. 
Ethanol exposure causes neuroapoptosis in the developing brain. Ethanol-induced loss of 
neurons in the central nervous system underlies many of the behavioral deficits observed in 
FASD. Excessive alcohol consumption is also associated with Wernicke–Korsakoff syndrome and 
neurodegeneration in the adult brain. Recent in vivo and in vitro studies indicate that lithium is 
able to ameliorate ethanol-induced neuroapoptosis. Lithium is an inhibitor of glycogen synthase 
kinase 3 (GSK3) which has recently been identified as a mediator of ethanol neurotoxicity. 
Lithium’s neuroprotection may be mediated by its inhibition of GSK3. In addition, lithium 
also affects many other signaling proteins and pathways that regulate neuronal survival and 
differentiation.  This review discusses the recent evidence of lithium-mediated protection against 
ethanol neurotoxicity and potential underlying mechanisms.
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deficits observed in FASD. Experimental models have been success-
fully used to investigate teratogenic effects of ethanol, and CNS 
abnormalities in FASD are replicated in experimental animal mod-
els. Neuronal loss is the most severe consequence of developmental 
exposure to ethanol. Chronic binge alcohol exposure also induces 
neurodegeneration in the adult brain and is associated with neu-
rocognitive deficits and Wernicke–Korsakoff syndrome (Obernier 
et al., 2002; Pfefferbaum et al., 2007; Harper, 2009). It is therefore 
important to identify potential neuroprotective agents that can 
ameliorate ethanol-induced CNS damage. This review discusses 
the evidence of lithium-mediated protection against ethanol neu-
rotoxicity and potential underlying mechanisms.
EvidEncE of lithium-mEdiatEd protEction against 
Ethanol nEurotoxicity
The development of the rodent brain during early postnatal days (the 
brain growth spurt) corresponds to that of the human third trimester 
and ethanol exposure during this period causes neurodegeneration 
(Olney et al., 2000). Injection of ethanol to C57BL/6 mice on postnatal 
day 7 (PD7) is a widely used animal model; acute ethanol exposure 
causes widespread apoptotic neurodegeneration in the brain of PD7 
mice (Olney et al., 2000; Young and Olney, 2006). Using this model 
system, investigators independently demonstrated that lithium was 
able to protect ethanol-induced neuroapoptosis (Zhong et al., 2006; 
Chakraborty et al., 2008; Young et al., 2008; Liu et al., 2009). In our 
study (Liu et al., 2009), PD7 C57BL/6 mice were injected subcutane-
ously with saline or ethanol (20% solution in saline, 2.5 g/kg) at 0 h 
and 2 h, and lithium was administrated intraperitoneally 30 min prior 
to ethanol exposure. Lithium effectively blocked ethanol-induced acti-
vation of caspase-3 and Bax in the developing cerebral cortex. Using 
introduction
Lithium is a classic mood stabilizer and it was the first drug approved 
by the Food and Drug Administration (FDA) in 1974 for mainte-
nance treatment of bipolar disorder (Pies, 2002). There has been a 
resurgence of interest in lithium due to studies that suggest lithium 
has neurotrophic and neuroprotective properties. Recent advances 
in cellular and molecular biology have shown that it may be useful 
in the treatment of acute brain injuries such as ischemia and chronic 
neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s 
disease (PD), Huntington’s disease (HD) and amyotrophic lateral 
sclerosis (ALS) (Marmol, 2008). Lithium has demonstrated diverse 
molecular  effects  reversing  well-described  pathophysiological 
changes such as increased oxidative stress, apoptosis, inflamma-
tion, environmental stress, glial dysfunction, neurotrophic factor 
deficiency, excitotoxicity as well as mitochondrial and endoplasmic 
reticulum disruption (Machado-Vieira et al., 2009). One of the 
most important neuroprotective properties of lithium is its anti-
apoptotic action (Bielecka and Obuchowicz, 2008).
Fetal Alcohol Spectrum Disorders (FASD) are caused by mater-
nal alcohol consumption during pregnancy and characterized by a 
spectrum of structural anomalies and neurocognitive and behavio-
ral disabilities (Riley and McGee, 2005). FASD currently represent 
the leading cause of mental retardation (Stratton et al., 1996; May 
and Gossage, 2001; Nash et al., 2008). Prominent central nervous 
system (CNS) abnormalities in FASD include: microencephaly, 
abnormal cortical thickness, reduced cerebral white matter vol-
ume, ventriculomegaly and cerebellar hypoplasia (Clarren et al., 
1978; Danis et al., 1981; Swayze et al., 1997; Archibald et al., 2001; 
Bookstein et al., 2006; Sowell et al., 2008). These alcohol-induced 
structural alterations in the brain underlie many of the   behavioral Frontiers in Neuroscience  |  Neuropharmacology    June 2010  | Volume 4  | Article 41  |  2
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PD7 mice, but had little effect on the phosphorylation at Tyr216 and 
the expression of total GSK3β (Liu et al., 2009). Saito et al. (2010) 
showed that ethanol increased the accumulation of caspase-cleaved 
tau, a substrate of GSK3β, in PD7 mice and lithium blocked ethanol-
mediated tau expression. The notion that lithium’s neuroprotection 
is mediated by its inhibition of GSK3β is further supported by the 
evidence that lithium blocks ethanol-induced down-regulation of 
p-GSK3β(Ser9) in PD7 mice (Chakraborty et al., 2008). Shaggy is 
the Drosophila homolog of GSK3β. Like lithium, a dominant nega-
tive Shaggy is able to block ethanol-induced apoptosis of olfactory 
neurons in adult Drosophila (French and Heberlein, 2009). Ethanol-
mediated activation of GSK3β is also observed in vitro. We demon-
strated that ethanol caused a strong dephosphorylation of GSK3β at 
Ser9 in N2a cells without affecting p-GSK3β(Tyr216) (Chen et al., 
2009). Ethanol-induced activation of GSK3β was evident by an 
increase in the phosphorylation of tau, a substrate of GSK3β. Similar 
to our observations, de la Monte and Wands (2002) demonstrated 
that prenatal ethanol exposure enhanced GSK3β activity in cultured 
cerebellar neurons. They also showed that ethanol activated GSK3β 
in cultured human CNS-derived primitive neuroectodermal tumor 
2 (PNET2) cells (Carter et al., 2008). However, it appears in the 
adult brain and some other cell types, ethanol may inhibit GSK3β. 
Neznanova et al. (2009) demonstrated that acute ethanol exposure, at 
a dose commonly regarded as reinforcing, strongly phosphorylated 
GSK3β at Ser9 in the medial prefrontal cortex, with corresponding 
increased phosphorylation of AKT in ethanol-preferring AA rats. 
They suggested the GSK3β pathway may be involved in high ethanol 
preference. In cardiac cells, ethanol increases p-GSK3β(Ser9) and 
inactivates GSK3β (Zhou et al., 2009).
To further establish the role of GSK3β in ethanol neurotox-
icity, we over-expressed wild type (WT), S9A mutant or kinase 
deficient (KD) GSK3β in SK-N-MC neuroblastoma cells, a cell 
line relatively insensitive to ethanol exposure. The KD and S9A 
GSK3β specifically inhibited and activated GSK3β, respectively. 
Over-expression of WT or S9A mutant GSK3β in SK-N-MC cells 
did not induce cell death, but greatly promoted ethanol-induced 
cell death of SK-N-MC cells; however, over-expression of KD 
GSK3β conferred resistance to ethanol neurotoxicity (Liu et al., 
2009). The involvement of GSK3β in ethanol neurotoxicity is fur-
ther supported by studies using specific GSK3β inhibitors. We 
showed that both lithium and TDZD-8 protected neuroblastoma 
cells over-expressing WT and S9A GSK3β from ethanol-induced 
cell death (Liu et al., 2009). TDZD-8 is a highly selective, non-ATP 
competitive inhibitor of GSK3β; it binds to the active site of GSK3β 
(Martinez et al., 2002). Takadera and Ohyashiki (2004) showed that 
two GSK3 inhibitors (SB216763 and alsteropaullone) completely 
eliminated apoptosis of primary rat cortical neurons in culture 
caused by ethanol exposure. The evidence supports that enhanced 
GSK3β activity indeed contributes to ethanol-induced neuronal 
death and lithium protection may be mediated by its inhibition 
of GSK3β. However, Zhong et al. (2006) showed that lithium pro-
tected cerebellar granule neurons from ethanol-induced apoptosis, 
but a selective GSK3β inhibitor (SB415286) did not. SB415286 is a 
GSK3 inhibitor structurally distinct from SB216763 and inhibits 
both GSK3α and GSK3β in an ATP competitive manner (Coghlan 
et al., 2000). They therefore suggested that GSK3 was not involved 
in ethanol-induced neurodegeneration.
a slightly different paradigm of lithium administration, Young et al. 
(2008) showed that the injection of lithium at the same time of etha-
nol exposure was sufficient to protect CNS neurons against ethanol-
induced neuronal death. Interestingly, lithium administration 15 min 
following ethanol exposure also provided effective protection against 
ethanol-induced neuroapoptosis (Zhong et al., 2006; Chakraborty 
et al., 2008). Using a Drosophila model, French and Heberlein (2009) 
showed that ethanol vapors caused apoptotic degeneration of olfac-
tory receptor neurons (ORNs) in adult Drosophila, and lithium pre-
vented ethanol-induced death of the ORNs. Lithium was also effective 
in preventing ethanol-induced neuroapoptosis in vitro and inhibited 
ethanol-induced activation of caspase-3 and caspase-9 in cultured 
cerebellar granule neurons (Zhong et al., 2006).
In addition to ameliorating ethanol-induced neurodegeneration, 
lithium is also shown to reverse ethanol-induced inhibition of neu-
ronal differentiation. We demonstrated that ethanol inhibited neurite 
outgrowth and the expression of neurofilaments in N2a neuroblas-
toma cells; lithium treatment alleviated ethanol’s inhibition (Chen 
et al., 2009). Using an in vitro model of neural stem cell (NSC) dif-
ferentiation, Ishii et al. (2008) found that ethanol inhibited neuronal 
differentiation of NSCs isolated from rat embryos. Lithium increased 
NSC differentiation and reduced ethanol-induced suppression of neu-
ronal differentiation. Ethanol activated neuron-restrictive silencer fac-
tor (NRSF), also known as repressor element-1 silencing transcription 
factor (Ishii et al., 2008). NRSF is a negative transcription factor that 
acts at the terminal stage of the neuronal differentiation pathway to 
block the transcription of neuronal differentiation genes, thus having 
an important role in determining the fate of NSCs. Lithium decreased 
the DNA binding activity and protein level of NRSF enhanced by 
ethanol (Ishii et al., 2008). Thus, both in vivo and in vitro evidence 
supports that lithium is able to ameliorate ethanol’s neurotoxicity.
involvEmEnt of gsK3β in lithium’s nEuroprotEction
An important function of lithium is to inhibit glycogen synthase 
kinase 3 (GSK3). GSK3 was originally found in mammals and 
homologs have been found in all eukaryotes (Grimes and Jope, 2001; 
Doble and Woodgett, 2003). GSK3 was named for its ability to phos-
phorylate, and thereby inactivate, glycogen synthase, a key regulatory 
molecule in the synthesis of glycogen. It is now known that GSK3 
plays an important role in the development of the CNS and regulates 
diverse early events, such as neurogenesis, neuronal migration, cell 
adhesion, synapse formation, neuronal survival and cell polarity/
neurite outgrowth in an immature brain (Luo, 2009). There are two 
highly homologous forms of GSK3 in mammals encoded by distinct 
genes, GSK3α (51 kDa) and GSK3β (47 kDa). Unlike most protein 
kinases, GSK3 is constitutively active in resting cells and undergoes 
a rapid and transient inhibition in response to a number of external 
signals (Grimes and Jope, 2001; Doble and Woodgett, 2003). GSK3β 
activity is regulated by site-specific phosphorylation. Full activity of 
GSK3β generally requires phosphorylation at tyrosine 216 (Tyr216), 
and conversely, phosphorylation at serine 9 (Ser9) inhibits GSK3β 
activity. Lithium inhibits the activity of both GSK3α and GSK3β and 
promotes inhibitory phosphorylation at Ser21 and Ser9 of GSK3α 
and GSK3β, respectively (Jope, 2003).
Available evidence indicates that ethanol can activate GSK3β in 
neurons. We demonstrated that ethanol induced a dephosphoryla-
tion of GSK3β at Ser9 [p-GSK3β(Ser9)] in the cerebral cortex of www.frontiersin.org  June 2010  | Volume 4  | Article 41  |  3
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Due to its diverse targets, the action of lithium may be complex 
and its neuroprotective property is sometimes controversial. For 
example, Fornai et al. (2008) demonstrated a marked neuroprotec-
tion by lithium in a mouse model of familial ALS (G93A mouse); 
lithium delayed disease onset and duration and augmented the 
life span. These effects were concomitant with the activation of 
autophagy. However, two recent reports indicated that chronic 
treatment of lithium failed to slow down disease progression in a 
mouse model of familial ALS (Gill et al., 2009; Pizzasegola et al., 
2009). We previously showed that lithium was effective in protect-
ing cultured neurons against 6-OHDA-induced apoptosis (Chen 
et al., 2004). Lithium’s protection against degeneration of dopamin-
ergic neurons, however, was not observed in an animal 6-OHDA 
model (data not shown).
conclusions and futurE rEsEarch
Lithium is a FDA-approved drug for use in the treatment of bipo-
lar disorder. Recent in vivo and in vitro studies have increasingly 
implicated that lithium is a neuroprotective agent efficacious in 
preventing apoptosis-dependent neuronal death. Available evi-
dence indicates that lithium is able to ameliorate ethanol-induced 
neuroapoptosis and inhibition of neuronal differentiation in vivo 
and in vitro, suggesting lithium may be useful for treating FASD. 
However, additional studies are needed to determine whether 
lithium’s ability to suppress developmental neuroapoptosis has 
any lasting consequences. For example, it is important to deter-
mine whether lithium is able to reverse ethanol-induced behav-
ioral deficits. Lithium has not been approved nor proposed for 
uses targeting the developing brain. The potential harmful side 
effects of lithium depend on the dose, duration of treatment 
and age of the patient at the time of treatment. It is unknown 
whether lithium has a negative impact on development. Lithium 
may have weak teratogenic effects in humans, but this has been 
described only after chronic exposure of the fetus during the 
first trimester of pregnancy (Gille and Bannigan, 2006). It has 
been shown that although lithium was effective at preventing 
excitotoxic motoneuron death by targeting GSK3β, this neuro-
protective effect was associated with conspicuous cytopathologi-
cal changes (Calderó et al., 2010), suggesting that lithium was 
unable to restore normal neuronal cytology. So far, there are no 
known toxic effects associated with exposure of either immature 
animals or humans to a single clinically relevant dose of lithium 
in late gestation or early childhood. However, before lithium 
administration could be recommended as a potential treatment 
against ethanol-induced neurotoxicity, a more complete safety 
evaluation is needed.
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In addition to mediating neuronal death, GSK3β also plays a role 
in ethanol-induced inhibition of neuronal migration and differen-
tiation. Aspartyl-asparaginyl-beta-hydroxylase (AAH) is a substrate 
of GSK3β and regulates cell motility (Carter et al., 2008). Ethanol 
induces GSK3β-dependent AAH phosphorylation, resulting in AAH 
degradation which impairs migration of neuronal cells (Carter et al., 
2008). Lithium mitigates ethanol-induced AAH protein degradation 
and impaired motility. We showed that ethanol inhibited neurite 
outgrowth by activating GSK3β through the dephosphorylation of 
GSK3β at Ser9 (Chen et al., 2009). Inhibition of GSK3β activity by 
specific inhibitors or down-regulation of GSK3β by siRNA reverses 
ethanol-induced inhibition of neurite outgrowth.
The mechanisms underlying GSK3β-mediated neurotoxicity are 
unclear. There are more than 40 substrates of GSK3β and many of 
them play an important role in neuronal survival and differentiation 
(Luo, 2009). Direct modifications of these downstream proteins as 
a result of GSK3β activation may induce ethanol neurotoxicity. For 
example, we demonstrated that ethanol activated pro-apoptotic Bax 
in a GSK3β-dependent manner in the developing mouse brain and 
in cultured neuronal cells (Liu et al., 2009). Saito et al. (2010) showed 
that ethanol caused an accumulation of caspase-cleaved tau which is a 
substrate of GSK3β and has been implicated in neurodegeneration in 
PD7 mice. AAH is also a substrate of GSK3β and regulates cell motility. 
Carter et al. (2008) found that ethanol induced a GSK3β-dependent 
AAH degradation and impaired the motility of neuronal cells.
othEr mEchanisms of lithium-mEdiatEd 
nEuroprotEction
In addition to targeting GSK3, lithium also affects the activity of 
other protein kinases/phosphatases, such as PKA and PP2A (Jope, 
2003; Sasaki et al., 2006; Liang et al., 2008). Lithium can directly or 
indirectly modulate proteins involved in neuronal survival/differ-
entiation independent of GSK3. For example, lithium is shown to 
promote the action of anti-apoptotic proteins, such as HSP, BDNF, 
IGF, VEGF, PKC, ERK, CREB, cAMP, Bcl-2, GRP78 and PI3K/AKT. 
It inhibits pro-apoptotic signaling such as the expression/activa-
tion of p53, Bax and tau (Bielecka and Obuchowicz, 2008; Marmol, 
2008; Machado-Vieira et al., 2009; Wada, 2009). ERK is believed to 
be a pro-survival factor in the developing brain, and Young et al. 
(2008) showed that ethanol suppressed the phosphorylation of ERK 
(p-ERK) in the brain of PD7 mice and lithium counteracted this 
effect. In their study, ethanol also suppressed p-AKT, but lithium 
did not counteract the suppression. They therefore suggested that 
lithium’s protection against ethanol-induced neuronal death in the 
developing brain was mediated by the promotion of ERK activity but 
not that of AKT (Young et al., 2008). In contrast, Chakraborty et al. 
(2008) demonstrated that lithium blocked ethanol-induced down-
regulation of p-AKT and p-AMPK in the forebrain of PD7 mice. 
These results suggest that lithium’s neuroprotection may be mediated 
by its promotion of anti-apoptotic signals or proteins and inhibition 
of pro-apoptotic proteins, which may not depend on GSK3.Frontiers in Neuroscience  |  Neuropharmacology    June 2010  | Volume 4  | Article 41  |  4
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